The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, Zhan J, Zhou T, Luo Q, Pan W, Zhang L, Lin C, Huang Y, Zhang L, Yang D, Zhao H.
Luo F, et al.
Cell Mol Immunol. 2024 Jan;21(1):60-79. doi: 10.1038/s41423-023-01112-y. Epub 2023 Dec 7.
Cell Mol Immunol. 2024.
PMID: 38062129
Free PMC article.